Amid a slew of shareholder lawsuits, a Congressional investigation, insider-trading allegations, and negative press surrounding its improperly manufactured coronavirus vaccine, it shouldn't surprise anyone to hear that over the past three years, Emergent BioSolutions (NYSE: EBS) has seen its shares fall by 90%.

With all of that in the rearview mirror, it's reasonable that some investors are now wondering if the only way things can go is up. 

And now that Emergent's valuation is cheaper than practically everything else's on the market, those investors might be right. But before you rush to buy this stock, let's evaluate the company's opportunities in the future. 

Continue reading

Source Fool.com